Results
eliminated by GSK-3␤ S9A ( Figure 2F ), perhaps due to the redistribution of membrane and cytoplasmic materials to the dendrites in the absence of an axon.
Polarized Distribution of a Phosphorylated Form
Neither the wild-type GSK-3␤ nor a kinase-dead form of GSK-3␤ in Hippocampal Neurons of GSK-3␤ affected axon-dendrite polarity (Figures 2C We used hippocampal neurons to investigate a potential and 2D). Wild-type GSK-3␤ reduced the length of axons role of GSK-3␤ in neuronal polarity. Hippocampal explants ( Figure 2E ) but did not affect the number or the length were isolated from embryonic day 18 (E18) rats and pyraof dendrites ( Figure 2F ). midal neurons were cultured (Banker and Cowan, 1977; Dotti and Banker, 1987; Brewer et al., 1993).
To determine the distribution of GSK-3␤ in hippocampal Formation of Multiple Axons after Inhibition of GSK-3 Activity by Pharmacological neurons, we double-labeled neurons with an antibody against total GSK-3␤ and another one against GSK-3␤
and Peptide Inhibitors and shRNAs To further test for a role of GSK-3 in neuronal polarity, we phosphorylated at Ser 9 (referred to as pGSK-3␤ hereafter). GSK-3␤ was detected in all neurites, both in st. Figure 3D ). Shortening of axons To test for a functional role of GSK-3␤ in the formation was observed in all experiments, described later in this of neuronal polarity, we used a constitutively active paper, when multiple axons formed. The length of den-GSK-3␤ mutant S9A, in which Ser 9 was replaced with drites was not affected by the pharmacological inhibialanine. Dissociated hippocampal neurons were transtors (data not shown). fected with a plasmid for the green fluorescent protein
We then used GID5-6, a peptide inhibitor of GSK-3␤ (GFP) or cotransfected with a plasmid for GFP and anderived from the GSK-3␤ interaction domain of axin other expressing GSK-3␤ S9A. Neurons were cultured (Hedgepeth et al., 1999) . The control GID5-6LP contained for 5 days before analysis of the axon-dendrite polarity a single amino acid mutation rendering it unable to interby the relative length of axons versus dendrites and by act with GSK-3␤ ( We also examined FM dye uptake by neurites from study the role of GSK-3␤ in establishing neuronal polar- ity, neurons were treated with SB415286 for the first 24 Neurons were cultured for 3 days to reach st. 3 before being treated with SB415286 or the control DMSO for hr and then removed. Neurons were cultured until day 6 (144 hr) before polarity examination. SB415286 caused another 3 days (from 72 to 144 hr) and were fixed for immunostaining on day 6. The majority of neurons the formation of multiple axons even when it was applied only for the first 24 hr ( Figures 5A and 5B) , indicating a treated with DMSO at day 3 developed normal polarity by day 6 ( Figure 5B ). SB415286 treatment from 72 to role for GSK-3␤ in establishing axon-dendrite polarity.
We examined how GSK-3␤ inhibition affected the dy-144 hr caused the formation of multiple axons ( Figure  5A , lower panel and Figure 5B ). It was almost as effective namics of neurite outgrowth by time lapse microscopy recording of st. 2 neurons ( Figure 5E , upper panels and as treatment from day 0 to day 6 ( Figure 5B ). These results suggest that SB415286 could affect the mainte- Figure 5D ). SB415286 significantly reduced the time spent on retraction but increased the time spent both nance of neuronal polarity. To further examine the maintenance role of GSK-3, we on pause and on growth ( Figure 5E , lower panels and Figure 5D ). The extent of the increase in pausing is less recorded individual neurites before and after SB415286 treatment on day 3 and then followed them to day 6. As than that of the decrease in retraction. The net effect was promoting the formation of longer neurites, presumexemplified in Figure 5C , there was one long neurite on day 3 (marked with a white arrow) and three shorter ably axons.
neurites from the same neuron (marked with a white or a yellow arrowhead) ( Figure 5C , left panel). On day 6, Role of GSK-3 in Maintaining Neuronal Polarity Tau-1 and MAP2 staining showed that the originally long The availability of chemical inhibitors for GSK-3 allows neurite (marked by the white arrow) was indeed an axon us to test whether there is an active mechanism for ( Figure 5C, right panel) . Interestingly, an additional axon maintaining neuronal polarity by applying them after the establishment of neuronal polarity.
was formed on day 6 (its end marked with the red arrow in the middle and right panels of Figure 5C ) from a neurite Relationship of GSK-3␤ with Akt in the Formation of Neuronal Polarity that was short on day 3 (its end marked with the yellow arrowhead in the left panel of Figure 5C suggests that it will be worthwhile to explore the approach to generate new axons from dendrites on adult is a major means to inactivate GSK-3␤. Our results with Akt and PTEN indicate that both are upstream of GSK-3␤ neurons with damaged axons. Before the therapeutic application can be tested, it in determining neuronal polarity. Akt functions to inhibit GSK-3␤ whereas PTEN functions to activate GSK-3␤.
will be necessary to investigate the feasibility of using GSK inhibitors to convert dendrites into axons in vivo Our results also provide evidence that Akt plays more roles than neuronal polarity because its activation could and in adult animals. The availability of pharmacological inhibitors of also increase the number of dendrites and the length of axons, neither of which could be caused by GSK-3␤ GSK-3␤ as well as inhibitors based on DNA and siRNA provide a range of potential therapeutic reagents for inactivation. They indicate that these roles of Akt are mediated by downstream components other than GSK-3␤, future tests. GSK-3␤ inhibition therefore offers a novel approach that may be used to induce axon conversion which only mediates the role of Akt in neuronal polarity.
